Despite comparable outcomes observed to date, several important factors should be considered when applying PSMA-targeted RLT in Asian patients, including differences in tumor aggressiveness, genomic profiles, and potential variations in treatment tolerance. The gene discussed is FOLH1; the disease is neoplasm.